April 3, 2013

Cover Story

CEO of the Year

Utah’s business landscape is rich with professionals who have le...Read More

Featured Articles

Did you go Skiing this winter?

Around Utah


Martin Plaehn

Karen Sendelback

Legal Briefs
Social Media and Employers: Friends or Enemies?

Money Talk
The Case for HSAs

Economic Insight
Time to Show Up

Lessons Learned
Make a Move

In the Lab

Rent to Own

Business Trends
Back from the Dead

Living Well
Artful Inspiration

A Breath of Fresh Air

Worst-Case Scenario

Regional Report
Northern Utah

Measure Up

Industry Outlook
Travel & Tourism



Predictive Biosciences Partners with ARUP Laboratories

Press Release

April 3, 2013

www.predictivebiosci.com%2F&esheet=50600852&lan=en-US&anchor=Predictive+Biosciences&index=1&md5=43febb8dbe397c248bb7ac6a239dcf66">Predictive Biosciences today announced a partnership withwww.aruplab.com&esheet=50600852&lan=en-US&anchor=ARUP+Laboratories&index=2&md5=90213de32db83b7197597eb08c532704"> ARUP Laboratories, a national reference laboratory and enterprise of the University of Utah, to offer the company’s molecular diagnostic bladder cancer tests to ARUP’s national network of clients.

Through a non-exclusive agreement, ARUP will offer Predictive’s CertNDx Bladder Cancer Assays in its comprehensive test menu to leading hospitals, healthcare providers, academic medical centers and military and government facilities around the country. ARUP’s clients will be able to order CertNDx testing, submit samples and receive all results through ARUP. Predictive Biosciences will run the diagnostic testing in its CAP and CLIA-certified laboratory.

“We are excited to begin our partnership with ARUP, a laboratory that shares our passion for innovation and technology,” said Pierre Cassigneul, chief executive officer at Predictive Biosciences. “We believe this alliance will greatly expand the availability of our bladder cancer products to a wider network of leading medical facilities that can benefit from CertNDx testing.”

The CertNDx Bladder Cancer Assay is a non-invasive, urine-based test to assess patients with hematuria and to monitor for bladder cancer recurrence after treatment. The test’s stratifies patients based on their likelihood of bladder cancer and is highly accurate across all stages and grades of bladder cancer. CertNDx testing is also available in a tissue-based prognostic test for molecular grading that can provide a quantitative molecular assessment of tumor grade including the likelihood of disease progression.

Utah Business Social
UB Events View All
Best Companies to Work For 2015Utah Business Event
Dec 10, 2015
Utah Business magazine is thrilled to announce the 2015 Best Companies to Work for Event! This y...
Community Events View All
Sandler Foundational Selling Strategies
Nov 24, 2015
How committed are you to improving your sales process, techniques and mindset? Sandler Trainin...
Empowering Self and Others: Become and Awakener
Dec 1, 2015
Uncover the secrets of empowerment. Whether you are a parent, a teacher or a Coach, you’ll find ...

info@utahbusiness.com  |  90 South 400 West, Ste 650 Salt Lake City, Utah 84101   |  (801) 568-0114

Advertise with Utah Business

Submit an Event

* indicates required information
* Event Name:
Price (general):
Website (if applicable):
Coordinator's Name:
Coordinator's Email:
Coordinator's Phone:
Venue Name:
Venue Address:
Venue City:
Venue Zip:
Event Capacity:
* Event Description: